GL1X · GenesisL1 explorer

MolNFT v1 · #150765 · protein

Introduction of a methyl group curbs metabolism of PYRIDO[3,4- D]PYRIMIDINE MPS1 inhibitors and enables the discovery of the phase 1 clinical candidate BOS172722.

6H3K · Dual specificity protein kinase ttk: “Introduction of a methyl group curbs metabolism of PYRIDO[3,4- D]PYRIMIDINE MPS1 inhibitors and enables the…”. X-ray diffraction, 1 ligand (FMW), 1 pocket (best druggability 0.77). MolNFT v1…

PDB
6H3K
Type
protein
Length
257 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Dual specificity protein kinase ttk
EC
2.7.12.1
UniProt
P33981
Ligands
FMW
Pockets
1 · best druggability 0.77

Structure

x-ray diffraction · 1 distinct chain · 36% helix, 21% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ADual specificity protein kinase ttk (EC 2.7.12.1)protein25736% helix, 21% strandP33981

Ligands and binding sites

  • FMW · ~{N}8-(2,2-dimethylpropyl)-~{N}2-[2-ethoxy-4-(4-methyl-1,2,4-triazol-3-yl)phenyl]-6-methyl-pyrido[3,4-d]pyrimidine-2,8-diamine · ligand · chains A
  • 7PE · 2-(2-(2-(2-(2-(2-ethoxyethoxy)ethoxy)ethoxy)ethoxy) ethoxy)ethanol · additive · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

1 pocket found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
12750.770.8934FMW

Compared structures

  • 6H3K · Introduction of a methyl group curbs metabolism of pyrido[3,4-d]pyrimidine MPS1… · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.